Various techniques have been tried in an endeavor to control deviant sexual drive. This paper presents the results obtained using a long-acting phenothiazine given intramuscularly and working on a depot basis, the theoretical advantages being a lesser incidence of gynecomastia than with estrogens, and the necessity for less patient cooperation than with oral medication. The results in both sexually normal and deviant groups suggest that the drug is of value in reducing sexual drive and performance, with no undue side effects observed provided antiparkinsonian drugs are given.Abstract Teaser